Welcome to our dedicated page for BioAge Labs news (Ticker: BIOA), a resource for investors and traders seeking the latest updates and insights on BioAge Labs stock.
BioAge Labs, Inc. develops clinical-stage biopharmaceutical candidates for cardiometabolic diseases by targeting the biology of human aging. Its news centers on BGE-102, a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for cardiovascular risk and retinal diseases, including diabetic macular edema.
Recurring updates cover Phase 1 biomarker and tolerability data, indication development for inflammation-driven disease, and research into long-acting injectable and oral small-molecule APJ agonists for obesity. BioAge also reports financial results, public offerings, R&D presentations, and collaborations that use its human longevity data platform to identify metabolic-aging pathways.
BioArctic AB (NASDAQ Stockholm: BIOA B) announced that the U.S. Veterans Health Administration (VHA) will cover LEQEMBI™ (lecanemab-irmb) for veterans with early-stage Alzheimer's disease. This decision comes two months post-FDA approval under the accelerated pathway. Healthcare professionals can prescribe LEQEMBI following VHA and FDA guidelines. The ongoing clinical trials aim to verify LEQEMBI's benefits, and further data is anticipated as Eisai prepares for traditional FDA approval. BioArctic has no development costs for lecanemab and is entitled to royalties and milestone payments from its commercialization.
BioArctic's partner, Eisai, announced that the FDA has accepted its supplemental Biologics License Application (sBLA) for LEQEMBI (lecanemab-irmb) for traditional approval, prioritizing the review. This follows its accelerated approval on January 6, 2023. The sBLA is based on the Phase 3 Clarity AD trial, which met its primary endpoint and key secondary endpoints. Eisai has a Prescription Drug User Fee Act (PDUFA) action date set for July 6, 2023. BioArctic is preparing for commercialization of LEQEMBI in the Nordics, having no development costs and receiving milestone payments and royalties on global sales.
BioArctic AB announced the recruitment of Anders Martin-Löf as the new CFO, effective June 1, 2023. Martin-Löf, who has over 20 years of experience in the Life Science sector, previously held roles at companies like Oncopeptides and A3P Biomedical. The current CFO, Jan Mattsson, will transition to a new role as VP Finance after Martin-Löf's arrival. Gunilla Osswald, the CEO, expressed confidence in Martin-Löf's capabilities to aid in the company's development during this exciting phase, particularly in treatments for neurodegenerative diseases. This change comes as BioArctic continues its partnership with Eisai on Alzheimer's therapies.
BioArctic AB announced that its partner Eisai's Biologics License Application (BLA) for lecanemab (LEQEMBI™) has been granted Priority Review by the National Medical Products Administration (NMPA) in China. This designation, aimed at expediting the approval process for clinically significant drugs, follows Eisai's submission of data, including results from the Phase 2b trial and the Phase III Clarity AD study on Alzheimer's disease. Lecanemab targets amyloid beta aggregates to potentially slow disease progression. BioArctic has no development costs for lecanemab and is entitled to milestone payments and royalties on global sales.
On January 30, 2023, BioArctic AB announced that its partner, Eisai, received Priority Review designation from the Japanese Ministry of Health for the marketing application of lecanemab (LEQEMBI™), an antibody for Alzheimer's disease (AD). The application, submitted on January 16, 2023, is based on results from the Phase 3 Clarity AD study, which demonstrated a significant reduction in clinical decline in early AD. Lecanemab has also received accelerated FDA approval in the U.S. for AD treatment. BioArctic is entitled to payments and royalties from lecanemab's sales, having no development costs associated with the drug.
BioArctic AB announced that its partner Eisai received acceptance from the European Medicines Agency (EMA) for a marketing authorization application (MAA) for lecanemab (brand name LEQEMBI) targeting early Alzheimer's disease.
This approval allows BioArctic to receive a milestone payment of MEUR 5. In the U.S., the drug received accelerated approval by the FDA on January 6, 2023, and Eisai is pursuing traditional approval based on positive Phase III results.
BioArctic has no developmental costs for lecanemab and is entitled to royalties on global sales and milestone payments.
On January 25, 2023, BioArctic AB announced the upcoming publication of its fourth quarter report for October-December 2022, set for February 3, 2022, at 08:00 CET. The company will host an audiocast at 09:30 CET the same day, where CEO Gunilla Osswald and CFO Jan Mattsson will present the report and participate in a Q&A session. BioArctic focuses on innovative treatments for neurodegenerative diseases, collaborating with global partners. Their Class B shares trade on Nasdaq Stockholm under the ticker BIOA B. For more details, visit their corporate website.
On January 16, 2023, BioArctic AB announced that its partner, Eisai, has submitted a marketing authorization application for lecanemab (brand name: LEQEMBI™) for early Alzheimer's disease treatment in Japan. The application follows Phase 3 Clarity AD study results, showing significant clinical decline reduction. BioArctic is entitled to a milestone payment of MEUR 5 upon acceptance by the PMDA. The FDA granted accelerated approval for lecanemab on January 6, 2023, with a supplemental application for full approval submitted on the same date. Eisai manages global development, while BioArctic prepares for commercialization in the Nordics.